The Influence of Radiological “Disappearing Lesions” on the Efficacy and Prognosis of Patients with Colorectal Liver Metastases Undergoing Conversion Therapy

Table 5

Univariate and multivariate analysis of progression-free survival.

Risk factors	Univariate analysis		Multivariate analysis
	HR (95% CI)	value	HR (95% CI)	value
Age (>/≤52, years)	4.532 (1.785-11.503)	0.001	3.690 (1.173-11.607)	0.026
Sex (male/female)	5.016 (1.753-14.349)	0.003	1.570 (0.430-5.736)	0.495
Size of liver metastasis (>/≤5 mm)	2.715 (0.806-9.143)	0.107
Primary site (colon/rectum)	1.476 (0.628-3.469)	0.372
Extrahepatic metastasis (yes/no)	1.002 (0.433-2.318)	0.996
T staging of the primary tumor	0.398 (0.103-1.536)	1.181
Lymph node metastasis (yes/no)	7.706 (0.936-63.390)	0.058
BMI (>/≤23.4)	0.646 (0.270-1.544)	0.326
CEA (>/≤5)	2.140 (0.889-5.152)	0.090
CA19-9(>/≤40)	0.930 (0.377-2.294)	0.875
Liver metastasis (simultaneous/metachronous)	1.441 (0.486-4.266)	0.510
Treatment regimens (chemotherapy alone/targeted therapy alone/chemotherapy combined with targeted therapy group)	2.593 (1.310-5.134)	0.006	2.703 (1.081-6.758)	0.033
Segment of liver metastases	0.928 (0.744-1.157)	0.506

Note: value <0.05. Abbreviations: PFS: progression-free survival; CI: confidence interval; BMI: body mass index; CEA: carcinoembryonic antigen; CA 19-9: carbohydrate antigen 199.